



Welcome to the CIHR / Rx&D Progress Report (2000 / 2001)

GIVING LIFE TO RESEARCH

CIHR / Rx&D Research Program
Director: Dr. David Brener

General Enquiries
[t] 613-941-6706
[w] www.cihr.ca
[e] dbrener@cihr.ca
mpeel@cihr.ca

MR1-10/2001-1
0-662-66251-2

A question of research

Dr. Hertzel

Gerstein of McMaster University is Principal Investigator on the DREAM trial, a study on diabetes prevention. Here, Dr. Gerstein talks about how the CIHR / Rx&D Research Program enables groundbreaking studies that impact the lives not only of those who suffer, but of all Canadians.

=====

Scientific research often begins with the flash of an intriguing thought, but only support — credibility, resources and collaboration — can produce a genuine opportunity to test important research questions. That's the impact the CIHR / Rx&D Research Program has in Canada.

Quite simply, my collaborator Dr. Salim Yusuf and I may not have been able to implement the DREAM clinical trial without CIHR / Rx&D. This program brings much more than funding to the table. The peer review process ensures that studies will be conducted rigorously, with the purest of scientific principles and the highest degree of ethics. Collaboration with CIHR also provides people who can facilitate the research. Thus, the CIHR / Rx&D program is an excellent example of partnership among government, academia and industry.

To my research colleagues, I would say that the CIHR / Rx&D program presents a good opportunity to work with industry partners to answer a worthy question. Good science, designed and led by Canada, generates international publicity, benefits from embedded Canadian values, and promotes a sense of national pride in the investigators. In addition, as you build research infrastructure, you enable research coordinators and scientific investigators to explore their careers in this country.

As a researcher, working with CIHR / Rx&D has shown me that the opportunity exists in Canada to harness resources that will meet the challenges of successful research. Through this bold team effort, CIHR / Rx&D works to remove obstacles from our path, leaving researchers free to probe scientific questions that are highly relevant to Canada, Canadians and the world at large.





***CIHR / Rx&D
RESEARCH PROGRAM***

OUR MISSION IS TO ENHANCE QUALITY
OF LIFE FOR THE WORLD'S PEOPLES
BY BRINGING TOGETHER ACADEMIA,
INDUSTRY AND GOVERNMENT.

WE FACILITATE COLLABORATIVE
PARTNERSHIPS THAT CREATE AND
TRANSFER KNOWLEDGE, DRIVING
FORWARD THE GOALS OF SCIENTIFIC
RESEARCH CONSISTENT WITH CANADA'S
STRATEGIC HEALTH RESEARCH
AGENDA, THE PHARMACEUTICAL
SECTOR, AND HEALTH CARE ON AN
INTERNATIONAL SCALE.



PARTNERING FOR LIFE

We are in the midst of a profound revolution in health research. This revolution will lead to an entirely new generation of medicines and other treatments, gene-based diagnosis of disease and disease pre-disposition, and an individualized health system based on the ability to uncover the intimate molecular alterations involved in disease and an individual's response to drugs.

This revolution requires that Canada catalyze strategic partnerships between academics researching all aspects of human health, and research-based pharmaceutical companies interested in guiding the evolution of this new knowledge toward improved human health.

The CIHR / Rx&D Research Program is designed to enable such partnerships, under conditions that respect and acknowledge academic values, the use of public funds, and the mandates of both CIHR and Canada's Research-Based Pharmaceutical Companies (Rx&D).

The Canadian Institutes of Health Research (CIHR) is Canada's lead agency for health research with a mandate from Parliament to excel in the creation of new knowledge through research, and to translate it into improved health for Canadians, a stronger health system and a more robust economy. Rx&D member companies represent the world's research-based pharmaceutical companies in Canada committed to the development, through research, of new drugs for the treatment of human diseases. By supporting research of the highest quality, the partnership between CIHR and Canada's Research-Based Pharmaceutical Companies (Rx&D) is helping to position Canada, Canadian investigators and companies as global leaders in this century of health research.



DR. ALAN BERNSTEIN, Ph.D., FRSC
President, Canadian Institutes of Health Research (CIHR)

MURRAY J. ELSTON
President, Canada's Research-Based Pharmaceutical Companies (Rx&D)

A NEW LANDSCAPE REVEALED

As commercial enterprises, Canadian and global pharmaceutical companies operate on a profit/loss system in an economically driven society. However, as health innovators, we also recognize a community obligation — and it is one that surpasses the corporate agenda. It is our responsibility — and our passion — to develop therapeutic strategies that improve health and enhance quality of life for Canadians and people around the world. This is our challenge, and I say

without hesitation that there is no better place in this world to meet this challenge than Canada.

This country presents us with a marvelous environment in which to undertake scientific enquiry. Canada offers a deep and wide talent pool, and a welcoming and productive infrastructure for medical science. Its government and institutions have taken on significant infrastructure commitments. Its university and hospital organizations are scientifically advanced and motivated. Indeed, to conduct scientific research in Canada is to make a statement of excellence. The CIHR / Rx&D Research Program provides pharmaceutical companies with access to that excellence.

I believe there is much common ground to be discovered between the investigator initiatives of the research community, the strategic initiatives being developed by CIHR through its institutes, and the research mandates of pharmaceutical companies, both individually and collectively. The CIHR / Rx&D Research Program enables opportunities to access expertise without compromise and with the highest scientific and ethical standards. This initiative unites the elements required to develop and deliver better health stratagems, alleviate suffering and improve quality of life for Canadians and others.

I encourage the world's research-based pharmaceutical companies to explore the unique research environment and collaborative opportunities that Canada's CIHR / Rx&D Research Program presents. When you invest in Canada's research capacity, you invest in your own futures and those of the people you are committed to serve.

Dr. Aldo Baumgartner is President and CEO of Wyeth-Ayerst Canada Inc. and Chairman (2000/2001) of Canada's Research-Based Pharmaceutical Companies (Rx&D). In this latter role, Dr. Baumgartner is the Canadian representative of the world's leading innovators in pharmaceutical development.

DELIVERING ON DISCOVERY

Today, health research has reached a nexus on an international scale. The promise of the genome project, compelling advancements in proteomics, and the convergence of diverse disciplines and technologies are providing unprecedented opportunities to the research community. The CIHR / Rx&D Research Program has been developed to unite researchers, industry and government in collaboration to capitalize on these opportunities for the ultimate benefit of Canadian health research, Canadian citizens, and people around the world.

CIHR / Rx&D is an innovative program of opportunity. We have wonderful resources available to us from universities, hospitals and pharmaceutical companies to attract interest in Canada as a preferred site for R&D. Health care has a high profile in Canada, and we have the public's support in our efforts to improve quality of life and to ease suffering. This program builds relationships among the critical sectors engaged in health research by facilitating increased interaction between Canada's Research-Based Pharmaceutical Companies (Rx&D) and research communities in our institutions.


Opinion polls continue to find health care the number one priority for Canadians. With health as our largest knowledge-based sector, Canada is amongst the world leaders in health research. We have a great opportunity in this country to develop the products, services and concepts that emanate from health research. CIHR supports this evolution to a leadership role through four strategic directions of special priority that address scientific opportunities. These directions, building on our country's research strengths and important health challenges, will bring about new knowledge of high impact that benefits not only Canadian society and economy, but also health and health care systems around the globe.

As its first direction, CIHR will build Canada's international leadership through national excellence in health research. We will strive to enhance and develop programs to attract the best and brightest of today's new scientists. Together with our partners, we have laid the groundwork that may, in future, enable us to augment the grant program we offer to these researchers, to launch even more innovative programs in support of research, and to invest more resources in our initiatives.

Second, CIHR will integrate the various disciplines of the health research spectrum, including life sciences, natural and social sciences, engineering, mathematics and the humanities. This accelerated convergence of multiple approaches will bring together new fields of study and new technologies in a synergistic relationship. As a partnership facilitator, CIHR / Rx&D will enable teams of relevant stakeholders in research and industry to come together and to learn from one another.

Third, CIHR will strive to improve the health status of vulnerable populations. Today, many Canadians, including those living in rural or remote areas, have limited access to the health system. CIHR has created five institutes that focus on the health of specific populations. In addition, the CIHR / Rx&D program will continue to support clinical trials that investigate, among other things, means of improving the health of these populations through cross-disciplinary or single disciplinary methods.

Finally, CIHR will strengthen health research and the health system in the genomics era. The approaches and information revealed in this new science will permeate health research and are fully supported by the CIHR / Rx&D program. In fact, Canada leads in the establishment of productive partnerships between funding agencies, researchers, industry and communities to move genetics from the laboratory to the clinic and the community.



The CIHR / Rx&D program supports these key directions that guide us along the path of international excellence. The research being funded is generating results that are furthering our country's research objectives and strategic initiatives, and more effectively delivering discoveries to the health care practitioner, the patient, and the public as a whole. In the upcoming pages of this Progress Report, you will see tangible evidence of our directions and palpable results of the CIHR / Rx&D program, presented in the form of case studies. These case studies demonstrate a fulfillment that is rarely seen today — fulfillment of academic goals, strategic objectives of a national health research agenda, industry mandates and, most importantly, the desire of Canadians for positive steps forward in their own well-being, today and tomorrow.

Dr. David Brener is the Director of the CIHR / Rx&D Research Program. Over the past two years, during the emergence of CIHR, Dr. Brener has applied a streamlined, practical approach to putting in place new and innovative programs that forward the goals of Canadian health research.

GIVING WINGS TO INNOVATION

It seems remarkable that humans and the common fruit fly (*Drosophila*) share many of the same protein characteristics, yet this simple insect may very well hold the key to many of life’s mysteries. In fact, the beginnings of new treatments for cancer, AIDS, depression and other diseases likely lie deep within this tiny creature. In July 2001, funded by a partnership between CIHR and GlaxoSmithKline through the CIHR/Rx&D Research Program, Dr. Henry Krause of the

University of Toronto and a team of researchers set out to study this most intriguing possibility.

Proteomics (the analysis of protein-protein interactions) is a follow-up opportunity presented by genomics and is a burgeoning field in biomedical health research. Protein interactions can trigger chemical reactions within cells that play a key role in many of today’s most devastating diseases. The study of protein location, interaction, structure and function aims to identify and characterize the proteins present in normal and diseased tissues. The ability to modulate proteins presents an attractive target for drug design.

The fruit fly grows and reproduces quickly, making it an ideal subject for health research study. As well, its biology is extremely well understood. By identifying the molecules and proteins that regulate the fruit fly’s nuclear receptors, researchers expect to gain new insights into the functions of the human body. Nuclear receptors are transcription factors that can be controlled by small hydrophobic molecules that have the ability to diffuse between and within cells.

This project is at the vanguard of a revolution in health research, causing a profound shift from disease treatment to disease prevention and health promotion. Thanks to a fruit fly, researchers can better understand the molecular mechanisms that underlie disease and develop a new arsenal of drugs that save lives — an outstanding example of the results of academic and industry collaboration through the CIHR / Rx&D Research Program.

“This program dramatically strengthens our ability to capture international research opportunities.”

JEAN-MICHEL HALFON
President & CEO, Pfizer Canada Inc.



-- Dr. Henry Krause --
Professor, Banting and Best Department of Medical Research,
University of Toronto

**MAKING GAINS
TO ELIMINATE
PAIN**

Pain — it is a feeling we have all experienced. The issue of pain treatment is an urgent health and socio-economic problem. Reliable and effective treatment and management of pain is of immense and immediate importance. Funded and facilitated by the CIHR / Rx&D Research Program and Pfizer Inc., Dr. Jean-Paul Collet, of McGill University is heading a study in the management stratagems of acute post-surgery pain management.

Despite recent dramatic advances in pain relief, nearly half of surgery patients still report moderate to severe pain, which research shows is affected by management methods, as well as patients' attitudes, beliefs and personalities. Through the Post-Operative Pain Management (POP-MAN) multi-centre study, seven hundred patients undergoing surgery for cholecystectomy, inguinal hernia repair, knee injury, abdominal hysterectomy, or postpartum perineal pain are being monitored. This study collects data on pain management procedures, determines levels of pain control, and assesses the impact of pain on quality of life during surgery, in the recovery room, throughout the hospital stay, convalescent and at home recovery periods. Results gleaned by Dr. Collet will yield material for better informing physicians, nurses and patients about treatment options that can be administered and managed on a national scale. Information from the study will also contribute to the Canadian Pain Society's Patient Pain Manifesto, an initiative to promote effective pain management.

Dr. Collet is involved in a broader mandate of pharmacoeconomics: assessing the consequences of drug use for patients, the place of therapeutics in disease control and the economics of drug prescription and use. Complementary leveraged funding offered by the CIHR / Rx&D Research Program enables Dr. Collet to undertake more comprehensive studies in a time-effective and collaborative environment. The result? The day may be closer than we think when post-surgery pain — a common experience of our time — becomes effectively managed.

“I’ve seen no other program in the world that compares to the CIHR / Rx&D Research Program.”

JOERG M. RUSTIGE, M.D.

Vice President, Research & Development, Eli Lilly Canada Inc.




-- Dr. Jean-Paul Collet --

Associate Professor of Epidemiology at McGill University,
Director of Randomized Clinical Trials at the Centre for Clinical
Epidemiology of the Jewish General Hospital,
Associate Director of Clinical Research at the Lady Davis
Institute of the Jewish General Hospital

The solid performance detailed below for the period January 2000 to December 2001 is based on the results of competitions held five times a year as well as eligible competitions reviewed outside of regular competitions.

ACTIVITY PROFILE AND PARTNER PARTICIPATION

(in millions of \$)



	Awards (\$)	Grants (\$)	Clinical Trials (\$)
Jan-June 2000	3,574,456	5,725,407	991,409
July-Dec 2000	2,324,210	1,705,716	2,678,040
Other* 2000	536,806	411,198	13,918,650
Jan-June 2001	3,362,735	4,367,811	4,495,658
July-Dec 2001	427,534	1,949,831	842,300
Other* 2001	1,214,890	1,825,346	17,760,000
Total	11,440,631	15,985,309	40,686,057

* within the stated calendar year but peer-reviewed outside of regularly scheduled competition


CONTRIBUTION OF FUNDED APPLICATIONS

	Rx&D cash (\$)	Rx&D in-kind (\$)	CIHR (\$)	Total (\$)
Jan-June 2000	6,582,336	576,016	3,132,920	10,291,272
July-Dec 2000	4,083,054	775,660	1,849,252	6,707,966
Other* 2000	11,415,739	0	3,450,915	14,866,654
Jan-June 2001	7,352,089	1,230,230	3,643,885	12,226,204
July-Dec 2001	2,010,025	444,778	764,862	3,219,665
Other* 2001	19,892,494	0	907,742	20,800,236
Total	51,335,737	3,026,684	13,749,576	68,111,997

All funded projects must pass CIHR peer review as a prerequisite for participation in industry partnered programs. All funds are directed to researchers in eligible Canadian institutions (ie. universities, hospitals). Canadian researchers located in other countries may also be eligible as well as Canadians participating in international programs. The tables and graphs herein show more than \$100M in industry partnered funded research for the period January 2000 to December 2001, of which over \$68M was partnered directly with Canada's Research-Based Pharmaceutical Companies (Rx&D). The increase in institutional spinoff ventures (included in CIHR / SME program figures) from research institutions is an increasingly significant contributor to Canada's Research-Based Pharmaceutical Companies (Rx&D) research agendas.

CUMULATIVE INDUSTRY PARTNERED RESEARCH ACTIVITY

(January 2000 – December 2001 / in millions of \$)



CIHR / SME: Largely companies that are spinoffs from research institutions and are actively seeking collaboration with Canada's Research-Based Pharmaceutical Companies (Rx&D).

* within the stated calendar year but peer-reviewed outside of regularly scheduled competition



Where vision comes to life Dr. Bruce

McManus is the Scientific Director of CIHR's Institute of Circulatory and Respiratory Health. In this message, he explains how Scientific Directors work within the CIHR / Rx&D Research Program to build a collaborative environment for furthering the goals of health research.

=====

The Scientific Directors who lead each of CIHR's thirteen institutes inspire the scientific creativity and the consciousness of community essential to the development and implementation of a national strategic framework for research. We build on the well-recognized foundation that defines Canada as a country committed to excellence in research, innovation and discovery. To accomplish this goal, we rely on the sage guidance of the research community and the wisdom of our Institute Advisory Boards.

Throughout the past year, we have engaged researchers, administrators, and the public from coast to coast, encouraging an awareness of the investigative power that can arise from the application of tools, technologies, and insights from wide-ranging disciplines and themes. We have fostered and built partnerships in support of science by engaging agencies and organizations from the private, public, and voluntary sectors. All partners are energized by this new openness and believe that such synergy will increase the chances for development and delivery of scientific discoveries to the benefit of all Canadians. Within a framework of partnership, we are setting clear agendas, determining appropriate funding for trials, and breaking down the barriers that otherwise plague research efforts.

The CIHR / Rx&D Research Program enables research of interest to all parties to be transformed into collaborative and high-impact endeavours. CIHR's institutes, working with Canada's Research-Based Pharmaceutical Companies (Rx&D) around the same table, have the opportunity to revolutionize health care and treatment in our society. Together with our partners, we are creating a climate of excellence and innovation for the health research communities to enhance our understanding of health and illness. The results will be evident in the scale and quality of research undertaken, in the knowledge transferred, and in the rising stars of scientific enquiry who come to know their country as the place to train and conduct research to enhance the quality of life for Canadians and all humanity.

Canada's Research-Based Pharmaceutical Companies improve the quality of life of all Canadians and enhance our health care system by fostering the discovery, development and availability of new medicines.


Abbott Laboratories, Limited	GlaxoSmithKline	Pfizer Canada Inc.
Actelion Pharmaceutiques Canada	Hemosol Inc.	Pharma Medica Research Inc.
Allergan Inc.	Hoffmann-La Roche Limited	Pharmacia Canada
AMGEN Canada Inc.	Infectio Diagnostic (I.D.I) Inc.	Procter & Gamble Pharmaceuticals Canada, Inc.
AstraZeneca Canada Inc.	Innovus Research Inc.	Purdue Pharma
Aventis Pharma	Investissement Québec	QLT Inc.
Axcan Pharma Inc.	Janssen-Ortho Inc.	Quest Clinical Trials Inc.
Bayer Inc.	Knoll Pharma Inc.	Quintiles Canada, Inc.
Berlex Canada Inc.	Labopharm Inc.	Ropack Inc.
Biomira Inc.	Leo Pharma Inc.	SGS Pharmaceutical Laboratories, A Division of SGS Canada Inc.
Boehringer Ingelheim (Canada) Ltd.	Lorus Therapeutics Inc.	Sanofi-Synthelabo Canada Inc.
Bristol-Myers Squibb Pharmaceutical Group	Lundbeck Canada Inc.	Schering Canada Inc.
Byk Canada Inc.	MDS Pharma Services Inc.	Servier Canada Inc.
ClinTrials BioResearch Ltd.	Merck Frosst Canada & Co.	Shire BioChem Inc.
Coley Pharmaceutical Canada	Neurochem Inc.	SOLVAY PHARMA Inc.
Danapharm Clinical Research Inc.	Novartis Pharmaceuticals Canada Inc.	Stiefel Canada Inc.
E-Z-EM Canada	NPS Allelix	Theratechnologies Inc.
Eli Lilly Canada Inc.	Nucro-Technics Incorporated	Tm Bioscience Corporation
Fournier Pharma Inc.	OSG Ivers-Lee Inc.	Tyco Healthcare Group Canada, Inc.
Fujisawa Canada Inc.	Organon Canada Ltd.	Wyeth-Ayerst Canada Inc.
Genome Canada	Paladin Labs Inc.	
	PDi-Research Laboratories Inc.	



Canada's Research-Based Pharmaceutical Companies

CIHR / Rx&D Research Program

STRENGTH IN NUMBERS



Appendix A —

CIHR / Rx&D AWARDS AND GRANTS

ALEXANDER, CHRISTOPHER	Fellowship	RUDDY, TERRENCE	
Mentor: PAUL HARRIGAN	/ 3 years	University of Ottawa	
St. Paul's Hospital		BRIDGE, PETER	
University of British Columbia		Alberta Children's Hospital	
GlaxoSmithKline	\$57,750	EXNER, DEREK	
CIHR	\$57,750	University of Calgary	
<i>Development and application of validated methodology utilising tandem mass spectrometry for the quantification of plasma antiretroviral drugs from patients with HIV and / or Hepatitis B or C</i>		Parke Davis Canada	\$641,486
		Parke Davis Canada (In-Kind)	\$453,768
		CIHR	\$320,743
		<i>Firefighters and their endothelium</i>	
ALTIER, NADÈGE	Fellowship	AU, BILLIE	Studentship
Mentor: MANON CHOINIÈRE	/ 2 years	Mentor: MELVIN SILVERMAN	/ 1 year
CHUM – Hospital Hôtel-Dieu		University of Toronto	
AstraZeneca Canada Inc.	\$50,150	Pfizer Canada Inc.	\$8,250
Canadian Pain Association		CIHR	\$8,250
Canadian Anesthesiologists' Society		<i>MD / PhD Program</i>	
CIHR	\$50,150		
<i>Quantitative sensory testing in burn patients experiencing chronic pain and / or paresthetic sensations in their healed burns</i>		BADDOUR, RALPH	Studentship
		Mentor: MELVIN SILVERMAN	/ 1 year
		University of Toronto	
		GlaxoSmithKline	\$8,250
		CIHR	\$8,250
		<i>MD / PhD Program</i>	
ANDERSON, TODD	Operating Grant		
University of Calgary	/ 5 years		
LONN, EVA			
Hamilton General Hospital			
CHARBONNEAU, FRANÇOIS			
McGill University			

BOIVIN, GUY Operating Grant
Université Laval / 3 years
GlaxoSmithKline \$225,000
CIHR \$112,500

A research program on influenza and other respiratory viruses: development and validation of rapid molecular detection methods and characterization of resistance mechanisms to neuraminidase inhibitors

BOIVIN, GUY Operating Grant
Université Laval / 2 years
ROY, JEAN
DELAGE, ROBERT
Hospital Maisonneuve-Rosemont (Montreal)
GlaxoSmithKline \$164,625
GlaxoSmithKline (In-Kind) \$39,510
CIHR \$82,312

Effect of valacyclovir in preventing reactivation of cytomegalovirus and other herpesviruses after allogeneic blood or bone marrow transplantation

BOSE, ROHIT Studentship
Mentor: MELVIN SILVERMAN / 1 year
University of Toronto
Pfizer Canada Inc. \$16,000
CIHR \$3,530

MD / PhD Program

BOUIN, MICKEAL Operating Fellowship
Mentor: PIERRE POITRAS / 2 years
CHUM – Hospital St-Luc
AstraZeneca Canada Inc. \$60,000
Canadian Association of Gastroenterology
CIHR \$60,000

Visceral hypersensitivity and functional digestive disorders

BOULIANNE, GABRIELLE Operating Grant
The Hospital for Sick Children / 2 years
University of Toronto
AstraZeneca Canada Inc. \$32,000
Alzheimer Society of Canada \$94,120
CIHR \$62,120

Genetic modifiers of presenilins

BOUTIN-GANACHE, ISABELLE Studentship
Mentor: CHRISTIAN DESCHEPPER / 2 years
Clinical Research Institute of Montreal
Université de Montréal
Pfizer Canada Inc. \$19,530
Canadian Hypertension Society
CIHR \$19,530

Identification of genetic factors related to cardiac hypertrophy through linkage analysis of cross-breeding and line generation

BOUVIER, MICHEL Operating Grant
Université de Montréal / 3 years
GlaxoSmithKline \$657,840
CIHR \$211,400

Oligomeric assembly in G-protein coupled receptor signalling

BRISSON, DIANE Studentship / 2 years
Mentors: DANIEL GAUDET, MARIE CLAUDE VOHL
Université Laval
Fournier Pharma Inc. \$30,000
CIHR \$9,060

Myotonic dystrophy: A model for genetic study of acylglycerol metabolism

CAMPBELL, JOHN Fellowship
Mentor: KENT HAYGLASS / 1 year
University of Manitoba
GlaxoSmithKline \$19,250
Canadian Allergy, Asthma and
Immunology Foundation
CIHR \$19,250

The role of chemokines in maintenance of established type 1 and type 2 cytokine responses to environmental antigens (allergens)

CASTEL, SAULO Fellowship
Mentors: SIDNEY KENNEDY, BRIAN RUSH / 1 year
The Centre for Addiction and Mental Health
University of Western Ontario
Wyeth-Ayerst Canada Inc. \$19,250
CIHR \$19,250

The assessment of the role of concurrent substance use and mental health disorders in the utilization abuse and community services and associated outcomes. An analysis of intake assessment and six month follow-up of CAMH substance use disorders treatment service data

CHAN, KWAN-LEUNG Clinical Trial
University of Ottawa Heart Institute / 5 years
TEO, KOON
TOMLINSON, CHARLES
McMaster University
KOILPILLAI, CHRIS
Queen Elizabeth II Health Sciences Centre
DUMESNIL, JEAN
Hospital Laval
SANFILIPPO, ANTHONY
Queen's University
JOYNER, CAMPBELL
Sunnybrook & Women's College Health Sciences Centre

SASSON, ZION
Mount Sinai Hospital
TAM, JAMES
Health Science Centre of Winnipeg
TUREK, MICHELE
Ottawa Hospital
JUE, JOHN
Vancouver General Hospital
SOCHOWSKI, RANDALL
University of British Columbia
GIANNOCCARO, PETER
CUJEC, BIBIANA
Walter Mackenzie Health Science Centre
HONOS, GEORGE
Sir Mortimer B. Davis – Jewish General Hospital

Bayer Inc. \$1,622,824
Bayer Inc. (In-Kind) \$649,510
CIHR \$405,706

Effect of cholesterol lowering on progression of aortic stenosis in patients with mild to moderate aortic stenosis

CHAUDHURY, PROSANTO Fellowship
Mentor: NICOLAS CHRISTOU / 1 year
McGill University

Bayer Inc. \$24,250
Canadian Infectious Disease Society
CIHR \$24,250

The role of PEDAM-1 in regulating polymorphonuclear neutrophil (PMN) transmigration and vascular leakage in sepsis

CHÉNIER, SÉBASTIEN Studentship
Mentor: MICHEL BOUVIER / 2 years
Université de Montréal
Pfizer Canada Inc. \$19,530
Canadian Hypertension Society

CIHR \$19,530

Role of G-protein in oligomeric assembly of the beta-adrenergic receptors

CHOW, ANTHONY Operating Grant
University of British Columbia / 1 year

MARRIE, THOMAS

University of Alberta

LOW, DONALD

University of Toronto

Bayer Inc. \$50,000

CIHR \$25,000

Etiological diagnosis of community acquired pneumonia by HSP60 dot blot analysis

CHULAK, CHANTAL Studentship
Mentor: JACQUES DE CHAMPLAIN / 1 year
Université de Montréal

Pfizer Canada Inc. \$9,765

Canadian Hypertension Society

CIHR \$9,765

Interaction between the sympathetic nervous system and endothelial factors in the mesenteric arteries of normal and hypertensive rats

COHN, JEFFREY Investigator
Clinical Research Institute of Montreal / 2 years
Université de Montréal

Merck Frosst Canada & Co. \$74,374

CIHR \$74,374

Plasma metabolism of triglyceride-rich lipoproteins and their remnants

COLLET, JEAN-PAUL Operating Grant / 1 year

Sir Mortimer B. Davis – Jewish General Hospital

McGill University

COGAN-COLLET, JENNIFER

Royal Victoria Hospital (Montreal)

CHOINIÈRE, MANON

CHUM – Hospital Hôtel-Dieu

BLAISE, GILBERT

Hospital Notre-Dame (Montreal)

CARLI, FRANCESCO

McGill University

VELLY, ANA

ROY, CHANTAL

Sir Mortimer B. Davis – Jewish General Hospital

Pfizer Inc. \$150,000

CIHR \$61,267

Post surgery management pain in Quebec: Pattern of practice and determinants of pain control

COLLET, JEAN-PAUL Operating Grant / 2 years

Sir Mortimer B. Davis – Jewish General Hospital

McGill University

SHAPIRO, STANLEY

McGill University

BOULET, LOUIS-PHILLIPE

Hospital Laval

ROULEAU, RACHEL

Université de Sherbrooke

Merck Frosst Canada & Co. \$119,840

CIHR \$59,500

Evaluation of the overall impact of pharmacist intervention on the maximization of symptom control in asthmatic individuals

D'AOUST, LOUISE Operating Fellowship
Mentor: BERNARD MESSING / 1 year

Hospital Lariboisière (France)

Schering Canada Inc. \$32,000

Canadian Association of Gastroenterology

CIHR \$34,500

Is insufficiency due to short bowel syndrome reduced by the use of intestinal trophic factors?

DAVIGNON, JEAN Operating Grant
Clinical Research Institute of Montreal / 3 years

Université de Montréal

LUSSIER-CACAN, SUZANNE

COHN, JEFFREY

BERNIER, LISE

Université de Montréal

DUFOUR, ROBERT

Clinical Research Institute of Montreal

Parke Davis Canada \$1,500,000

CIHR \$562,850

Lipid, lipoproteins and human disease

DAVIGNON, JEAN Operating Grant
Clinical Research Institute of Montreal / 1 year

Université de Montréal

ROY, MADELEINE

DUFOUR, ROBERT

Clinical Research Institute of Montreal

Novartis Pharmaceuticals Canada Inc. \$200,000

CIHR \$80,000

Genetic determinants of atherosclerosis

De REPENTIGNY, LOUIS Operating Grant
Université de Montréal / 2 years

BELHUMEUR, PIERRE

Université de Montréal

Merck Frosst Canada & Co. \$91,200

CIHR \$45,600

Studies on differentially expressed virulence genes in the fungal pathogen Candida albicans

DER SARKISSIAN, SHANT Studentship
Mentor: DENIS DEBLOIS / 1 year

Université de Montréal

Pfizer Canada Inc. \$9,765

Canadian Hypertension Society

CIHR \$9,765

Role of kinins in cardiovascular cell fate in hypertension

DICKO, AWA Operating Fellowship
Mentor: JOAN BOGGS / 2 years

The Hospital for Sick Children

University of Toronto

AstraZeneca Canada Inc. \$100,000

Multiple Sclerosis Society of Canada

CIHR \$62,000

Study of myelin glycolipids and proteolipid protein by biophysical techniques

DiLEO, VINCENZA Operating Fellowship
Mentor: MARY PERDUE / 2 years

McMaster University

AstraZeneca Canada Inc. \$62,400

Canadian Association of Gastroenterology

CIHR \$61,600

Permeability of the intestinal mucosal barrier in food allergy / inflammation

DOUGLAS, DONNA Fellowship
Mentor: NORMAN KNETEMAN / 2 years

University of Alberta

Wyeth-Ayerst Canada Inc. \$38,500
 Health Canada \$25,664
 CIHR \$12,836

Antisense oligonucleotide inhibition of Hepatitis C viral replication in a small animal model for human Hepatitis C viral infection

DRANNIK, ANNA Operating Fellowship
 Mentor: MARTIN STAMPFLI / 2 years
 McMaster University

AstraZeneca Canada Inc. \$100,000
 Canadian Thoracic Society
 Canadian Lung Association
 CIHR \$25,000

Development of a murine model of viral-induced chronic airway inflammation

DUSSAULT, SYLVIE Studentship
 Mentor: ROBERT BISSONNETTE / 1 year
 Université de Montréal

Leo Pharma Inc. \$19,530
 CIHR \$19,530

Photodynamic therapy with toluidine blue as an ex vivo purging agent for the treatment of leukemia

DUTIL, JULIE Studentship
 Mentor: ALAN DENG / 2 years
 CHUM – Hôtel-Dieu Campus

Pfizer Canada Inc. \$19,530
 Canadian Hypertension Society
 CIHR \$19,530

Identification of blood pressure genes in the Dalh Salt-Sensitive hypertension model

ELIMADI, AZIZ Fellowship
 Mentor: PIERRE HADDAD / 1 year
 Université de Montréal

Axcan Pharma Inc. \$12,750
 Schering Canada Inc. \$6,500
 Canadian Association for the Study of the Liver
 CIHR \$19,250

Role of mitochondrial permeability transition in cold preservation-warm reoxygenation injury in rat liver

FINELLI, ANTONIO Fellowship
 Mentors: KEITH JARVI, LORI BURROWS / 1 year
 Toronto General Hospital
 University of Toronto

GlaxoSmithKline \$16,667
 Bayer Inc. \$16,667
 Canadian Infectious Disease Society
 CIHR \$15,166

Analysis of gene expression in Pseudomonas aeruginosa biofilms

FRASER, PAUL Operating Grant
 University of Toronto / 2 years
 Neurochem Inc. \$357,200
 Neurochem Inc. (In-Kind) \$124,900
 CIHR \$161,190

Amyloid and disease: Experimental models and therapeutic development

GANGULI, SUBHAS Fellowship
 Mentor: GERVAIS TOUGAS / 2 years
 McMaster University

SOLVAY PHARMA Inc. \$55,000
 Canadian Association of Gastroenterology

CIHR \$8,737

The autonomic nervous system in inflammatory bowel disease

GENEST, JACQUES Research Chair
 McGill University / 5 years

Novartis Canada Pharmaceuticals Inc. \$350,000
 CIHR \$350,000

Genetic determinants of high density lipoproteins: ABC A1 transporter and cellular cholesterol efflux

GENEST, JACQUES Operating Grant
 McGill University / 3 years

Parke Davis Canada \$331,680
 CIHR \$160,840

ABC1 gene and cholesterol efflux

GERSTEIN, HERTZEL Clinical Trial
 McMaster University / 5 years

Aventis Pharma \$1,630,000
 Aventis Pharma International \$1,630,000
 King Pharmaceuticals \$7,400,000
 CIHR \$3,258,650

Diabetes reduction approaches with ramipril and rosiglitazone medications (DREAM)

GERSTEIN, HERTZEL Clinical Trial
 McMaster University / 5 years

YUSUF, SALIM
 LONN, EVA
 Hamilton General Hospital
 DAGENAIS, GILLES
 Université Laval

TEO, KOON
 ANAND, SONIA
 CAPES, SARAH
 McMaster University
 CHIASSON, JEAN-LOUIS

CHUM
 ZINMAN, BERNARD
 University of Toronto
 McQUEEN, MATTHEW
 St. Joseph's Hospital
 RYAN, EDMOND
 Heritage Medical Research Centre

GlaxoSmithKline \$17,760,000
 CIHR

Diabetes reduction approaches with ramipril and rosiglitazone medications (DREAM)

GILL, SHARLENE Fellowship
 Mentor: RICHARD GOLDBERG / 1 year
 Mayo Clinic, Minnesota

GlaxoSmithKline \$35,750
 Canadian Association of Medical Oncologists
 CIHR \$24,250

Clinical research fellowship in gastrointestinal oncology

GINSBERG, JEFFREY Research Chair
 McMaster University / 5 years

AstraZeneca Canada Inc. \$350,000
 CIHR \$350,000

Management of venous thromboembolism

GINZBERG, HEDY Operating Fellowship
 Mentor: GREGORY DOWNEY / 2 years

The Hospital for Sick Children
 University of Toronto

AstraZeneca Canada Inc. \$62,400
Canadian Association of Gastroenterology
CIHR \$62,400

Neutrophil mediated injury to intestinal epithelium: importance of adherens junctions

GIRARDOT, DAPHNÉ Studentship
Mentor: PIERRE MOREAU / 1 year
Université de Montréal

Pfizer Canada Inc. \$9,765
Canadian Hypertension Society
CIHR \$9,765

Heterogeneous regulation of cell growth by nitric oxide in cardiovascular tissues

GRENIER, SONYA Fellowship / 2 years
Mentors: PIERRE BORGEAT, SYLVAIN BOURGOIN
CHUL
Université Laval

Wyeth-Ayerst Canada Inc. \$38,500
CIHR \$38,500

Study of PLD function in neutrophils

GUI, YU Studentship
Mentor: MORLEY HOLLENBERG / 1 year
University of Calgary

Pfizer Canada Inc. \$9,765
Canadian Hypertension Society
CIHR \$9,765

Proteinase-activated receptors and renal vascular function

HALE, TABEN Studentship
Mentor: MICHAEL ADAMS / 1 year
Queen's University

Pfizer Canada Inc. \$9,765
Canadian Hypertension Society
CIHR \$9,765

Induction of rapid and sustained regression of CVS: assessment of mechanisms involved

HAO, DESIREE Fellowship
Mentor: ERIC ROWINSKY / 1 year
University of Texas

GlaxoSmithKline \$35,000
Janssen-Ortho Inc.
Canadian Association of Medical Oncologists
CIHR

Drug development fellowship

HARRIS, STEWART Clinical Trial
University of Western Ontario / 2 years
BROWN, JUDITH
HOCH, JEFFREY
TOKMAKEJIAN, SONYA
University of Western Ontario

Bayer Inc. \$87,431
Bayer Inc. (In-Kind) \$22,248
CIHR \$26,730

The impact and cost-effectiveness of point-of-care testing on the management of patients with type 2 diabetes in a group family practice setting

HOGG, JAMES Operating Grant
University of British Columbia / 3 years
HAYASHI, SHIZU
St. Paul's Hospital

GlaxoSmithKline \$304,914
GlaxoSmithKline (In-Kind) \$113,016
CIHR \$127,997

The mechanism of steroid resistance in COPD

HOLLENBERG, MORLEY Operating Grant
University of Calgary / 2 years
Servier Canada Inc. \$111,533
Servier Canada Inc. (In-Kind) \$100,000
CIHR \$55,767

Identification of novel endothelial derived contracting factor & its vascular receptor

HUYNH, HIEN Operating Fellowship
Mentor: PHILIP SHERMAN / 2 years
The Hospital for Sick Children
University of Toronto

AstraZeneca Canada Inc. \$60,000
Canadian Association of Gastroenterology
CIHR \$60,000

Host responses to cage positive Helicobacter pylori

IJIMA, HIROAKI Fellowship
Mentor: DAVID EIDELMAN / 1 year
McGill University

GlaxoSmithKline \$18,480
Canadian Lung Association
CIHR \$10,010

Role of protein nitration and eosinophilia in a murine mode of asthma

IJON, HUMBERTO Operating Fellowship
Mentor: KAREN MADSEN / 2 years
University of Alberta

AstraZeneca Canada Inc. \$60,000
Canadian Association of Gastroenterology
CIHR \$60,000

Role of poly-ADP-ribose polymerase in the control of NF- κ B activity

JOHNSTON, CÉLESTE Operating Grant
McGill University / 1 year

VON BAEYER, CARL
University of Saskatchewan
COGAN-COLLET, JENNIFER
Royal Victoria Hospital
SHAPIRO, STANLEY
McGill University
CHOINIÈRE, MANON
CHUM – Hospital Hôtel-Dieu
WATT-WATSON, JUDITH
University of Toronto
COLLET, JEAN-PAUL
Sir Mortimer B. Davis – Jewish General Hospital

Pfizer Canada Inc. \$54,252
Pharmacia Canada \$54,252
CIHR \$53,443

Patient Pain Manifesto: A pilot study of efficacy

KALISCH, BETTINA Operating Fellowship
Mentor: REBECCA RYLETT / 2 years
University of Western Ontario

AstraZeneca Canada Inc. \$100,000
Alzheimer Society of Canada
Canadian Congress of Neurological Sciences
CIHR \$20,000

Studies on mechanisms involved in nerve growth factor enhancement of cholinergic gene expression with relevance to treatment in Alzheimer's disease

KENNEDY, JAMES Studentship
Mentor: MELVIN SILVERMAN / 1 year
University of Toronto

			/ x
Pfizer Canada Inc. CIHR	\$8,250 \$8,250	GlaxoSmithKline CIHR	\$8,250 \$8,250
<i>MD / PhD Program</i>			

KLEIN, MARINA McGill University LALONDE, RICHARD DESCHÊNES, MARC McGill University ANGEL, JONATHAN Ottawa Hospital BERNARD, NICOLE Montreal General Hospital Research Institute RACHLIS, ANITA Sunnybrook & Women's College Health Sciences Centre ROULEAU, DANIELLE Université de Montréal	Operating Grant / 3 years	KUMAR, DEEPALI Mentors: ALLISON McGEER, JOYCE DEAZAVEDO Mount Sinai Hospital University of Toronto GlaxoSmithKline Canadian Infectious Disease Society CIHR	Fellowship / 1 year \$24,250 \$24,250

GlaxoSmithKline CIHR	\$77,778 \$32,408	LATOUR, MARTIN Mentor: WILFRED LAUTT University of Manitoba GlaxoSmithKline Canadian Association for the Study of the Liver CIHR	Fellowship / 1 year \$37,420
<i>A phase II, open-label pilot study to examine the efficacy and safety of a combination therapy with simultaneous activity against Hepatitis C and HIV in co-infected patients</i>			

KRAUSE, HENRY University of Toronto ARROWSMITH, CHERYL EDWARDS, ALED Ontario Cancer Institute GlaxoSmithKline GlaxoSmithKline (In-Kind) CIHR	Operating Grant / 2 years \$1,500,000 \$100,000 \$598,411	LATTERMANN, RALPH Mentor: FRANCESCO CARLI McGill University AstraZeneca Canada Inc. Canadian Pain Society Canadian Anesthesiologists' Society CIHR	Operating Fellowship / 2 years \$100,000 \$20,000
<i>Proteomics of Drosophila nuclear receptors</i>			

KRUGER, JOSHUA Mentor: GREGORY DOWNEY University of Toronto	Studentship / 1 year	<i>Understanding the mechanisms of perioperative substrate utilization during analgesia with epidural local anesthetic</i>	

			/ xi
LAUPLAND, KEVIN Mentor: HERBERT DAVIES Alberta Children's Hospital University of Calgary Bayer Inc. Canadian Infectious Disease Society CIHR	Fellowship / 1 year \$33,333 \$15,167	<i>Incidence and risk factors for acquiring invasive Staphylococcus aureus infection in Calgary: a population-based study</i>	

Le MAY, MICHEL University of Ottawa Heart Institute Guidant Corp. Inc. (In-Kind) Hoffmann-La Roche Limited (In-Kind) CIHR	Clinical Trial / 3 years \$241,230 \$367,600 \$149,408	<i>Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI Study)</i>	

LEBEL, SYLVIE Mentor: NICOLA JONES The Hospital for Sick Children University of Toronto Axcan Pharma Inc. Canadian Association for the Study of the Liver CIHR	Fellowship / 1 year \$24,250 \$24,250	<i>Pathogenesis of Helicobacter hepaticus mediated gastrointestinal and liver disease</i>	

LEE, AGNES Hamilton Civic Hospital McMaster University	New Investigator / 5 years		

Pharmacia Canada CIHR	\$137,500 \$137,500	<i>Thromboembolic disease in the cancer patient</i>	

LEHNER, RICHARD University of Alberta VANCE, DENNIS University of Alberta GlaxoSmithKline CIHR	Operating Grant / 3 years \$672,160 \$247,200	<i>Role of human triacylglycerol hydrolase in triacylglycerol metabolism</i>	

LEVY, GARY Toronto General Hospital University of Toronto Novartis Pharmaceuticals Canada Inc. CIHR	Research Chair / 5 years \$400,000 \$350,000	<i>Immunopathogenesis of viral hepatitis</i>	

LI, DANIEL Mentor: NICHOLAS COUPLAND University of Alberta Wyeth-Ayerst Canada Inc. CIHR	Fellowship / 2 years \$48,500 \$48,500	<i>Facial emotion recognition in social phobia, depression and generalized anxiety disorder</i>	

LI, GANG University of British Columbia	Operating Grant / 1 year		
Leo Pharma Inc. CIHR	\$50,000 \$25,000		

Role of bax and caspase-3 in melanoma chemosensitivity: in vivo and in vitro analysis

LI, TIMAO Fellowship
Mentor: GUY BEAULIEU / 2 years
TPP Health Canada
Canada's Research-Based
Pharmaceutical Companies (Rx&D) \$51,332
Health Canada \$12,834
CIHR \$12,834

Regulatory reviews of cardiovascular drug submissions and analysis of all available data to investigate the possible relationship between adverse events and angiotensin converting enzyme inhibitors

LIN, AMY Studentship
Mentor: MELVIN SILVERMAN / 1 year
University of Toronto
GlaxoSmithKline \$8,250
CIHR \$8,250

MD / PhD Program

LIN, FRANK Operating Fellowship
Mentor: PHILIP SHERMAN / 2 years
The Hospital for Sick Children
University of Toronto
AstraZeneca Canada Inc. \$60,000
Canadian Association of Gastroenterology
CIHR \$60,000

Modelling of adhesion of Helicobacter pylori to mucosal surfaces

LIU, HONG WEI Operating Fellowship
Mentor: ANDREW HALAYKO / 2 years
University of Manitoba
AstraZeneca Canada Inc. \$100,000
Canadian Lung Association
Canadian Thoracic Society
CIHR \$49,400

Airway smooth muscle cell phenotype: post-transcriptional regulation of hypertrophy and cholinergic responsiveness

LIU, HONG-QUN Fellowship
Mentor: SAMUEL LEE / 1 year
University of Calgary
Axcan Pharma Inc. \$44,520
Canadian Association for the Study
of the Liver
CIHR

Nitric oxide and cirrhotic cardiomyopathy

LIU, XUEJUN Operating Fellowship
Mentors: MICHAEL SALTER, JOHN RODER / 2 years
The Hospital for Sick Children
University of Toronto
AstraZeneca Canada Inc. \$82,260
Canadian Pain Society
Canadian Anesthesiologists' Society
CIHR \$62,000

Roles of PKC-gamma neurons in the dorsal spinal cord

LOURENCO, CELIA Fellowship
Mentor: ANTHONY RIDGWAY / 2 years
TPP Health Canada
Canada's Research-Based
Pharmaceutical Companies (Rx&D) \$51,332
Health Canada \$12,834

CIHR \$12,834
Biological and radiopharmaceutical drug reviews and regulatory framework analysis and development for positron emission tomography drugs

LOURENSSEN, SANDRA Operating Fellowship
Mentor: MICHAEL BLENNERHASSETT / 1 year
Queen's University
Axcan Pharma Inc. \$51,000
Canadian Association of Gastroenterology
CIHR \$5,000

Role of glutamate receptor bearing neurons in intestinal function

LUCAS, GUILLAUME Fellowship
Mentor: GUY DEBONNEL / 2 years
McGill University
Wyeth-Ayerst Canada Inc. \$38,500
CIHR \$38,500

Role of 5-HT4 receptors in the control of the serotonergic raphe-hippocampal transmission

LUKE, PATRICK Fellowship / 1 year
Mentors: ROBERT ZHONG, ANTHONY JEUNIKAR
University of Western Ontario
Wyeth-Ayerst Canada Inc. \$24,250
CIHR \$24,250

Characterization of the mechanisms of CD45RB monoclonal antibody-mediated tolerance induction

MADORE, ÉRIC Fellowship
Mentor: MICHEL FORTIER / 2 years
Université Laval

Wyeth-Ayerst Canada Inc. \$38,500
CIHR \$38,500

Endometrial prostaglandins and gynecological disorders

MALARVANNAN, PANNIRSELVAM Studentship
Mentor: CHRISTOPHER TRIGGLE / 2 years
University of Calgary
Pfizer Canada Inc. \$19,530
Canadian Hypertension Society
CIHR \$19,530

Endothelium function in blood vessels from diabetic human and animal models of diabetes

MARCEL, YVES Operating Grant
University of Ottawa Heart Institute / 2 years
TESSON-RULKO, FEDERIQUE
McPHERSON, RUTH
University of Ottawa Heart Institute
GlaxoSmithKline \$205,430
CIHR \$102,091

Incidence of cellular lipid efflux deficiency in hypoalphalipoproteinemia

McFAWN, PETER Fellowship
Mentor: JOHN FISHER / 1 year
Queen's University
GlaxoSmithKline \$18,480
Canadian Lung Association \$10,010
CIHR \$10,010

Bronchoscopic video imaging of airway narrowing. Role of the airway wall

McGEER, EDITH Operating Grant
University of British Columbia / 2 years

AstraZeneca Canada Inc. \$33,792
 Alzheimer Society of Canada \$99,391
 CIHR \$65,598

Neurotoxic effects of inflammatory cytokines in vitro

McGEER, PATRICK Operating Grant
 University of British Columbia / 2 year

AstraZeneca Canada Inc. \$33,210
 Alzheimer Society of Canada \$97,674
 CIHR \$64,466

Relationship of inflammatory cytokine polymorphisms to Alzheimer disease pathology

McGILVRAY, IAN Fellowship
 Mentor: GARY LEVY / 2 years
 Toronto General Hospital
 University of Toronto

Wyeth-Ayerst Canada Inc. \$48,500
 CIHR \$48,500

The role of fgl-2 / fibroleukin in acute rejection and tolerance induction

McMASTER, ROBERT Operating Grant
 University of British Columbia / 1 year

Aventis Pharma \$138,000
 CIHR \$47,254

Analysis of M. tuberculosis and macrophage gene expression by microarray technology

MÉNARD, ISABELLE Studentship
 Mentor: MICHAEL GRESSER / 5 years
 Merck Frosst Research Institute

Merck Frosst Canada & Co. \$188,825
 Merck Frosst Canada & Co. (In-Kind) \$1,250

CIHR \$48,825

Study of the temporal and spatial profile of capase-3 activation in transection model for neurodegeneration

MESHI, BERNARD Operating Fellowship
 Mentor: JAMES HOGG / 2 years
 University of British Columbia

AstraZeneca Canada Inc. \$100,000

Canadian Lung Association
 Canadian Thoracic Society
 CIHR \$62,000

Steroid response and latent adenoviral infection in cigarette smoke-induced emphysema in guinea pigs

MICHALAK, ERIN Fellowship
 Mentor: RAYMOND LAM / 2 years
 University of British Columbia

Wyeth-Ayerst Canada Inc. \$38,500
 CIHR \$38,500

Clinical trial networks for treatment of seasonal depression and depression in primary care

MILLETTE, ESTHER Studentship
 Mentor: DANIEL LAMONTAGNE / 1 year
 Université de Montréal

Pfizer Canada Inc. \$9,765

Canadian Hypertension Society
 CIHR \$9,765

Intracellular mechanisms involved in alterations in coronary reactivity caused by hypertension, studied in the isolated heart model, supplemented by biomolecular techniques

MITCHELL, LESLEY Operating Grant
 The Hospital for Sick Children / 2 years
 University of Toronto

MASSICOTTE, PATRICIA
 The Hospital for Sick Children

Leo Pharma Inc. \$280,304
 CIHR \$90,498

A dose finding study of low molecular weight heparin in children with thromboembolic events

MOLDOVAN, FLORINA New Investigator
 CHUM – Hospital Notre-Dame / 3 years

Pfizer Canada Inc. \$82,500
 CIHR \$82,500

Involvement of endothelin (ET-1) in human osteoarthritic cartilage

MONTANER, JULIO Clinical Trial
 St. Paul's Hospital / 3 years
 University of British Columbia

Hoffmann-La Roche Limited \$400,000
 CIHR \$81,850

An open-label randomised study to evaluate the antiretroviral effect, tolerability, safety and pharmacokinetics of Saquinavir SGC / Ritonavir QD vs. Indinavir / Norvir BID in HIV infected patients

MONTANER, JULIO Clinical Trials
 St. Paul's Hospital / 3 years
 University of British Columbia

GlaxoSmithKline \$501,500
 CIHR \$65,800

Randomized, open-label study of continued stavudine vs. abacavir substitution with or without riboflavin and

thiamine supplementation in patients with elevated lactic acid while on stavudine-based therapy

NAIMARK, DAVID Operating Grant
 Sunnybrook & Women's College / 2 years
 Health Sciences Centre

University of Toronto
 TOBE, SHELDON
 DAVIS, DAVID

University of Toronto
 BOTT, MICHELLE
 NICKELL, LESLIE

POLDRE, PETER
 Sunnybrook & Women's College Health Sciences Centre
 REZNIK, RICHARD

University Health Network (Toronto)
 HUX, JANET
 Institute for Clinical Evaluative Sciences (Toronto)

Aventis Pharma \$38,500
 Pfizer Canada Inc. \$25,000
 CIHR \$16,750

Facilitating the adoption of clinical practice guidelines. Promotion of urine microalbuminuria screening among primary care physicians: A randomised, educational intervention trial

NATAH, SIRAJEDIN Operating Fellowship
 Mentor: KEITH SHARKEY / 2 years
 University of Calgary

AstraZeneca Canada Inc. \$60,000
 Canadian Association of Gastroenterology
 CIHR \$60,000

Autonomic nervous system in colitis

NONG, YI Operating Fellowship
Mentor: MICHAEL SALTER / 2 years
The Hospital for Sick Children
University of Toronto

AstraZeneca Canada Inc. \$100,000
Canadian Pain Society
Canadian Anesthesiologists' Society
CIHR \$17,560

A novel signalling pathway for sensitizing excitatory synaptic transmission in the dorsal horn of the spinal cord

OWEN, DAWN Studentship
Mentor: MELVIN SILVERMAN / 1 year
University of Toronto

GlaxoSmithKline \$16,000
CIHR \$3,530

MD / PhD Program

PASIC, IVAN Studentship
Mentor: MELVIN SILVERMAN / 1 year
University of Toronto

GlaxoSmithKline \$16,000
CIHR \$3,530

MD / PhD Program

PETRELLA, ROBERT Investigator
University of Western Ontario / 5 years

Pharmacia Canada \$260,000
CIHR \$192,500

Activity and healthy aging: translating basic science to primary care research

PETRELLA, TERESA Fellowship / 1 year
Mentors: DAVID SPANER, NEIL BERINSTEIN
University of Toronto

GlaxoSmithKline \$35,750
Canadian Association of Medical Oncologists
CIHR \$24,250

The role of interferon- α after vaccination in the treatment of melanoma

POIRIER, JUDES Operating Grant
Douglas Hospital Research Institute / 2 years
McGill University

AstraZeneca Canada Inc. \$34,000
Alzheimer Society of Canada \$100,000
CIHR \$66,000

HMG -CoA reductase: A novel candidate gene for sporadic Alzheimer's disease

POWERS, KINGA Fellowship
Mentor: ORI ROTSTEIN / 1 year
Toronto General Hospital
University of Toronto

GlaxoSmithKline \$33,333
Canadian Infectious Disease Society
CIHR \$15,167

LPS receptor modulation following hemorrhagic shock

PRINGSHEIM, TAMARA Fellowship
Mentors: ÉDITH HAMEL, MICHEL AUBE / 1 year
McGill University

GlaxoSmithKline \$27,500
Canadian Congress of Neurological Sciences
Canadian Headache Society
CIHR \$19,250

Investigation of brain serotonin status in patients with chronic daily headaches using Positron Emission Tomography (PET): effects of treatment and comparative studies in an animal model

RAMOS-BARBON, DAVID Operating Fellowship
Mentors: ELIZABETH FIXMAN, / 2 years
JAMES MARTIN
McGill University

AstraZeneca Canada Inc. \$100,000
Canadian Lung Association
Canadian Thoracic Society
CIHR \$25,000

The role of T cell activation in the development of airway remodeling in asthma

REN, FENGGE Fellowship
Mentors: DIANE PROVENCHER, / 2 years
ANNE-MARIE MES-MASSON
CHUM – Hospital Notre-Dame

Wyeth-Ayerst Canada Inc. \$38,500
CHIR \$38,500

The use of signature expression patterns in the molecular histology of epithelial ovarian cancer

REUTER, BRIAN Operating Fellowship
Mentor: MARK MILLER / 1 year
Albany Medical College NY

SOLVAY PHARMA Inc. \$27,500
Canadian Association of Gastroenterology \$5,000
CIHR \$34,000

Treatment of gastrointestinal cancer with natural vanilloids

ROBICHAUD-EKSTRAND, SYLVIE Operating Grant
Université de Montréal / 2 years

SPINEAULT, RAYNALD
BOURASSA, MARTIAL
Université de Montréal
TAMBLYN, ROBYN
McGill University
CHIASSON, JEAN-LOUIS
CHUM – Hospital Hôtel-Dieu
DUPUIS, GILLES
Montreal Institute of Cardiology

Merck Frosst Canada & Co. \$50,000
Eli Lilly Canada Inc. \$5,000
CIHR \$27,500

Impact of an iterative computer-tailored feedback system on continuity of care in the management of cardiovascular risk factors and health behaviours in CAD and type 2 diabetic patients

ROCCA, ANTONIO Studentship
Mentor: MELVIN SILVERMAN / 1 year
University of Toronto

Novartis Pharmaceuticals Canada Inc. \$16,000
CIHR \$9,765

MD / PhD Program

ROCKWOOD, KENNETH Clinical Trial
Dalhousie University / 2 years
MACKNIGHT, CHRISTOPHER
Dalhousie University

Janssen-Ortho Inc. \$1,821,611
CIHR \$455,399

Evaluating the effect of galantamine HBr using goal attainment scaling (GAS) in a placebo controlled trial of mild to moderate Alzheimer's disease subjects

ROPELESKI, MARK Operating Fellowship
Mentor: EUGENE CHANG / 1 year
University of Chicago (Illinois)

Byk Canada Inc. \$35,000
Canadian Association of Gastroenterology
CIHR \$25,000

Intestinal epithelial heat shock protein responses in models of injury and inflammation

ROPELESKI, MARK Operating Fellowship
Mentor: EUGENE CHANG / 1 year
University of Chicago (Illinois)

Schering Canada Inc. \$32,000
CIHR \$38,222

Intestinal epithelial heat shock protein responses in models of injury and inflammation

ROY, MARIE-ODILE Fellowship / 1 year
Mentors: SULTAN AHMAD, THIERRY GROBLEWSKI
AstraZeneca R&D Montréal

AstraZeneca Canada Inc. \$26,000
CIHR \$19,250

Identification and characterization of the ligands for novel / orphan G-protein coupled receptors

ROY, PRAVEEN Operating Fellowship
Mentor: WILLIAM PATERSON / 1 year
Queen's University

Janssen-Ortho Inc. \$31,747
Canadian Association of Gastroenterology
CIHR \$31,747

Studies on the mechanisms of esophageal longitudinal muscle hyper-responsiveness in acid-induced esophagitis

SAIBIL, SAM Studentship
Mentor: MELVIN SILVERMAN / 1 year
University of Toronto

GlaxoSmithKline \$8,250
CIHR \$8,250

MD / PhD Program

SALAPATEK, ANNE MARIE Operating Grant
University of Toronto / 2 years

Abbott Laboratories, Limited \$60,000
Canadian Association of Gastroenterology
CIHR \$30,000

Novel SNARE-K⁺ channel interactions modulate esophageal smooth muscle contractility

SAMADDER, JEWEL Studentship
Mentor: MELVIN SILVERMAN / 1 year
University of Toronto

Novartis Pharmaceuticals Canada Inc. \$16,000
CIHR \$3,530

MD / PhD Program

SANCHEZ, ANA Operating Fellowship
Mentor: DEREK McKAY / 2 years
McMaster University

AstraZeneca Canada Inc. \$62,400
Canadian Association of Gastroenterology \$1,222
CIHR \$62,400

Adenoviral gene transfer of IL-6-type cytokines as an anti-inflammatory therapy

SEACHRIST, JENNIFER Studentship
Mentor: STEPHEN FERGUSON / 2 years
John P. Robarts Research Institute

University of Western Ontario

Pfizer Canada Inc. \$19,530
Canadian Hypertension Society
CIHR \$19,530

Beta 2-adrenergic and angiotensin II type 1A receptor trafficking and endocytosis are regulated by interactions with Rab GTPases and Beta-arrestins

SÉGUIN, ROSANNE Operating Fellowship
Mentor: JACK ANTEL / 2 years
Montreal Neurological Institute
McGill University

AstraZeneca Canada Inc. \$100,000
Multiple Sclerosis Society
Canadian Congress of Neurological Sciences
CIHR \$25,000

To determine the mechanisms by which microglia functions are modulated by neutrophils, to limit their involvement in the pathogenesis of MS and to enhance a beneficial effect of axonal growth

SELBY, RITA New Investigator
Sunnybrook & Women's College / 5 years
Health Sciences Centre
University of Toronto

Pharmacia Canada \$125,000
CIHR \$125,000

Clinically-important venous thromboembolism after below knee fractures: epidemiology & prevention

SELBY, RITA Clinical Trial
Sunnybrook & Women's College / 2 years
Health Sciences Centre
University of Toronto

GEERTS, WILLIAM
University of Toronto
KREDER, HANS
OH, PAUL
SZALAI, JOHN
HAMILTON, PAUL
Sunnybrook & Women's College Health Sciences Centre
CROWTHER, MARK
St. Joseph's Hospital

Pharmacia Canada \$707,848
Pharmacia Canada (In-Kind) \$75,000
CIHR \$195,712

Clinically-important venous thromboembolism following lower extremity fractures: epidemiology & prevention

SEYMOUR, MICHELLE Operating Fellowship
Mentor: WALLACE MacNAUGHTON
University of Calgary

SOLVAY PHARMA Inc. \$27,500
Canadian Association of Gastroenterology \$5,000
CIHR \$27,500

Trafficking of GFP-tagged CFTR in intestinal epithelial cells

SHAH, SALONI Fellowship
Mentor: JAMES MARTIN / 1 year
Meakin's Christite Labs
McGill University

GlaxoSmithKline \$18,480
Canadian Lung Association \$10,010
CIHR \$10,010

5'-phosphatase in airway responsiveness

SHARPE, COLIN Operating Grant / 2 years
Sir Mortimer B. Davis – Jewish General Hospital
McGill University

COLLET, JEAN-PAUL
 Sir Mortimer B. Davis – Jewish General Hospital
 RICHARDSON, JOHN
 BOIVIN, JEAN-FRANÇOIS
 HANLEY, JAMES
 McGill University
 MARCUS, VICTORIA
 Montreal General Hospital Research Institute
 Merck Frosst Canada & Co. \$71,767
 CIHR \$35,652

Pilot study to measure the effects of NSAID use on angiogenesis and apoptosis in female invasive breast cancer

SHEN, GARRY Operating Grant
 University of Manitoba / 1 year
 WOO, VINCENT
 Health Sciences Centre of Winnipeg
 PENNER, S.
 University of Manitoba
 Merck Frosst Canada & Co. \$52,500
 CIHR \$26,250

Effect of losartan on the production of extracellular matrix and their modulators in patients with diabetes mellitus

SILVERBERG, MARK Operating Fellowship
 Mentors: KATHERINE SIMINOVITCH, / 2 years
 ALLAN STEINHART
 University of Toronto
 AstraZeneca Canada Inc. \$62,400
 Canadian Association of Gastroenterology \$200
 CIHR \$62,400

Identification of genes for inflammatory bowel disease and its complications

SIMALA-GRANT, JOANNE Operating Fellowship
 Mentor: DIANE TAYLOR / 1 year
 University of Alberta

AstraZeneca Canada Inc. \$31,200
 Canadian Association of Gastroenterology
 CIHR \$31,200

Helicobacter pylori and gastric carcinogenesis

SIUSHANSIAN, RAMIN Fellowship
 Mentor: CATHY PETERSON / 2 years
 TPP Health Canada

Canada's Research-Based
 Pharmaceutical Companies (Rx&D) \$51,332
 Health Canada \$12,834
 CIHR \$12,834

Regulatory reviews of central nervous system drugs and a comparative assessment of special populations information in product monographs for anti-epileptic drugs

SONG, DAISHENG Fellowship
 Mentor: SAMUEL LEE / 1 year
 University of Calgary
 GlaxoSmithKline \$19,250
 Canadian Association for the Study of the Liver
 CIHR \$19,250

Mechanism of Fos effects in central neural regulation of the hyperdynamic circulation of portal hypertension: dependence on CREB

SOUSSI GOUNNI, ABDELILAH Fellowship
 Mentor: QUATYBA HAMID / 1 year
 Meakins-Christie Laboratories
 McGill University
 GlaxoSmithKline \$19,250

Canadian Allergy, Asthma and
 Immunology Foundation
 CIHR \$19,250

IL-9 effects in eosinophils associated cytokine receptors (IL-5, GM-CSF and IL-4)

STURMER, MARCIO Fellowship
 Mentor: DENIS ROY / 1 year
 Université de Montréal

Wyeth-Ayerst Canada Inc. \$19,250
 CIHR \$19,250

Ultra low-dose trial of amiodarone in atrial fibrillation (ULTRA)

SU, BIN Operating Fellowship
 Mentor: PHILIP SHERMAN / 3 years
 University of Toronto

AstraZeneca Canada Inc. \$150,000
 Canadian Association of Gastroenterology
 CIHR \$37,500

Host cell signal transduction response to Helicobacter pylori infection

SURESH BABU, PODA Fellowship
 Mentor: SULTAN AHMAD / 1 year
 AstraZeneca R&D Montreal

AstraZeneca Canada Inc. \$26,000
 CIHR \$19,250

Identification and characterization of the ligands for novel / orphan G-protein coupled receptors

TAI, ISABELLA Operating Fellowship
 Mentor: LAN CHEN / 1 year
 Dana Farber Cancer Institute (Boston)

Axcan Pharma Inc. \$25,500
 Canadian Association of Gastroenterology \$9,000
 CIHR \$25,500

Microarray gene expression profiles of colon cancer resistant to therapy

THOTTINGAL, PAUL Fellowship
 Mentor: FRANCIS PLUMMER / 1 year
 University of Manitoba

GlaxoSmithKline \$24,250
 Canadian Infectious Disease Society
 CIHR \$24,250

Mucosal immune responses to HIV-1 highly exposed seronegative sex workers

TINMOUTH, JILL Operating Fellowship
 Mentor: ALLAN STEINHART / 1 year
 Mount Sinai Hospital
 University of Toronto

GlaxoSmithKline \$51,000
 Canadian Association of Gastroenterology
 CIHR \$12,768

Lactose intolerance in HIV-positive patients with chronic non-infectious diarrhea

TOBE, SHELDON Clinical Trial
 Sunnybrook & Women's College / 2 years
 Health Sciences Centre

University of Toronto
 PYLYPCHUK, GEORGE
 Saskatoon Medical Specialists
 SZALAI, JOHN
 University of Toronto
 NAIMARK, DAVID
 BOTT, MICHELLE
 Sunnybrook & Women's Health Sciences Centre

Pharmacia Canada \$220,000
 CIHR \$55,000
DREAM 3 – Diabetes risk evaluation and microalbuminuria in Saskatchewan first nations people

VAN KAMPEN, CORINNE Operating Fellowship
 Mentor: STEPHEN COLLINS / 1 year
 McMaster University
 Janssen-Ortho Inc. \$30,638
 Canadian Association of Gastroenterology
 CIHR \$30,638
Th1 and Th2 colitides

VAN KATS, JORGE Fellowship
 Mentor: TIMOTHY REUDELHUBER / 2 years
 Clinical Research Institute of Montreal
 Université de Montréal
 Bristol-Myers Squibb Pharmaceutical Group \$30,917
 Canadian Hypertension Society
 CIHR \$23,917
Angiotensin II and cardiac hypertrophy

VANCE, DENNIS Operating Grant
 University of Alberta / 2 years
 Bayer Inc. \$220,000
 CIHR \$78,300
Role of phosphatidylethanolamine N-methyl transferase (PEMT) in the secretion of very low density lipoproteins (VLDL) from liver

VERGNOLLE, NATHALIE Operating Grant
 University of Calgary / 2 years
 Byk Canada Inc. \$40,000
 Canadian Association of Gastroenterology

CIHR \$20,000
Intestinal inflammation mediated by proteinase-activated receptors

WANG, LU Operating Fellowship
 Mentor: CHUN SEOW / 1 year
 University of British Columbia
 AstraZeneca Canada Inc. \$50,000
 Canadian Lung Association
 Canadian Thoracic Society
 CIHR \$30,975
Cellular mechanisms of airway smooth muscle plasticity: role of actin remodeling

WANG, XUAN YU Operating Fellowship
 Mentor: JAN HUIZINGA / 1 year
 McMaster University
 Janssen-Ortho Inc. \$28,547
 Canadian Association of Gastroenterology
 CIHR \$28,547
(Patho)-physiology of interstitial cells of Cajal

WATSON, CAROLE Fellowship
 Mentors: VICTOR HAN, ALAN BOCKING / 2 years
 University of Western Ontario
 Wyeth-Ayerst Canada Inc. \$38,500
 CIHR \$38,500
Molecular mechanisms of fetal programming following intrauterine growth restriction

WEI, ZELAN Operating Fellowship
 Mentor: XIN-MIN LI / 2 years
 Royal University Hospital
 University of Saskatchewan

AstraZeneca Canada Inc. \$100,000
 Alzheimer Society of Canada
 CIHR \$62,000
Neuroprotective effects of antipsychotics: Implications for treatment of Alzheimer's disease

WESTALL, CAROL Operating Grant
 The Hospital for Sick Children / 3 years
 University of Toronto
 LOGAN, WILLIAM
 SNEAD, ORLANDO
 BUNCIC, JOSEPH
 The Hospital for Sick Children
 Aventis Pharma \$207,000
 CIHR \$70,187
Visual function in infants and children treated with vigabatrin

WILD, GARY Operating Grant
 Montreal General Hospital / 2 years
 McGill University
 BITTON, ALAIN
 SZILAGYI, ANDREW
 McGill University
 STEINHART, ALLAN
 Mount Sinai Hospital
 THOMSON, ALAN
 University of Alberta
 Schering Canada Inc. \$50,000
 Schering Canada Inc. (In-Kind) \$446,400
 CIHR \$196,000

The role of infliximab as monotherapy for the treatment of Crohn's disease and its effect on surrogate markers of Tumour necrosis factor (TNF) expression in the colonic mucosa

WISHART, DAVID Research Chair
 University of Alberta / 5 years
 Bristol-Myers Squibb Pharmaceutical Group \$250,000
 CIHR \$250,000

Novel NMR approaches to high throughput protein structure determination

WONG, STEPHEN Fellowship
 Mentor: GERALD MINUK / 1 year
 University of Manitoba
 British Columbia Centre for Disease Control
 GlaxoSmithKline \$24,250
 Canadian Association for the Study of the Liver
 CIHR \$24,250

The prevalence of viral hepatitis and primary biliary cirrhosis in the first nations population of Canada

XU, HAIYUN Fellowship
 Mentor: XIN-MIN LI / 2 years
 Royal University Hospital
 University of Saskatchewan
 Wyeth-Ayerst Canada Inc. \$38,500
 CIHR \$38,500

Neuroprotective effects of antidepressants

XU, JIANHUA Fellowship
 Mentor: M.C. GANOZA / 2 years
 University of Toronto
 Pharmacia Canada \$50,000
 CIHR \$38,500

Studies on the mechanisms of protein biosynthesis with a novel antibiotic probe

ZHANG, JI Fellowship
Mentor: DEJAN O'DONNELL / 1 year
AstraZeneca R&D Montreal

AstraZeneca Canada Inc. \$26,000
CIHR \$19,250

Mapping CNS distribution of novel G-protein coupled receptors

ZHENG, PENG Fellowship / 1 year
Mentors: NICOLA JONES, SERGIO GRINSTEIN
The Hospital for Sick Children
University of Toronto

Abbott Laboratories, Limited \$40,000
Canadian Association of Gastroenterology
CIHR \$20,000

Mechanisms underlying Helicobacter pylori disrupted phagocytosis

ZINMAN, BERNARD Clinical Trial
Mount Sinai Hospital / 3 years
University of Toronto

DRUMMOND, KEITH
Montreal Children's Hospital
DONNELLY, S.
Toronto General Hospital
Merck Frosst Canada & Co. \$684,000
CIHR \$171,000

Renin angiotensin system blockade: diabetic nephropathy (BASS)

Appendix B —

CIHR / Rx&D WORKSHOPS TO DATE

AVOLI, MASSIMO
McGill University

*Focus on Epilepsy VI – Treatment of epileptic syndromes:
From molecular targets to quality of life*

Pfizer Canada Inc. \$7,600
Novartis Pharmaceuticals Canada Inc. \$10,000
Abbott Laboratories, Limited \$15,200
Draxis Health Inc. \$15,200
Savoy Pharma \$4,000
CIHR \$5,000

CHOINIÈRE, MANON
CHUM – Hospital Hôtel-Dieu

Pain 2001: An odyssey of discoveries. Canadian Pain Society Annual Conference

Pharmacia Canada \$30,000
AstraZeneca Canada Inc. \$10,000
Janssen-Ortho Inc. \$54,500
Pfizer Canada Inc. \$25,000
Purdue Pharma \$15,000
CIHR \$5,000

CHRÉTIEN, MICHEL
Loeb Health Research Institute

International symposium on proteases: Basic aspects and clinical relevance

Pfizer Canada Inc. \$5,000

Bristol-Myers Squibb Pharmaceutical Group \$5,000
CIHR \$5,000

COUTURE, RÉJEAN
Université de Montréal

Peptide Receptors – Montréal 2001, from gene to therapy

Astra Pain Research Unit \$10,000
Boehringer Ingelheim (Canada) Ltd. \$3,000
BioChem Pharma Inc. \$3,000
Merck Frosst Canada & Co. \$1,000
Servier Canada Inc. \$2,000
Eli Lilly Canada Inc. \$5,000
Institut de Recherches International Servier \$7,500
Merck & Co. Inc. \$15,200
Aventis Pharma \$7,600
BioSignal \$5,000
Sanofi-Synthelabo Canada Inc. \$5,000
CIHR \$5,000

DAVIES, PETER
Queen's University

From the genome to structure and function

Canadian Institute for Advanced Research \$2,000
University of Toronto \$5,000
Queen's University \$1,000
McGill University \$8,000
John P. Robarts Institute \$1,000
AstraZeneca Canada Inc. \$1,500

Merck Frosst Canada & Co.	\$1,500	Pulmonex Research	\$1,000
Amersham Pharmacia Biotech Inc.	\$1,500	AstraZeneca Canada Inc.	\$4,000
Bruker Daltronics Ltd.	\$500	Eli Lilly Canada Inc.	\$10,000
Bruker Canada Inc.	\$500	Mallinckrodt Canada Inc.	\$5,000
Institute of Genetics	\$5,000	3M Canada Inc.	\$3,000
Virtek Vision Corp.	\$2,000	Bristol-Myers Squibb Pharmaceutical Group	\$1,000
Imaging Research Inc.	\$2,000	Pfizer Canada Inc.	\$15,000
Biophysical Society of Canada	\$1,000	Bayer Inc.	\$2,000
VWR Canlab	\$1,700	GlaxoSmithKline	\$2,000
Beckman Coulter Canada Inc.	\$1,500	Pharmacia Canada	\$1,500
CedarLane Laboratories Ltd.	\$1,500	Aventis Pharma	\$5,000
Sun Microsystems	\$5,000	Brathwaites Olivier Medical Inc.	\$2,000
Micromass Canada Inc.	\$4,400	Edwards Lifesciences	\$2,000
Canadian Genetic Diseseses Network	\$1,000	Byk Canada Inc.	\$15,000
AMGEN Canada Inc.	\$1,520	Alliance Pharmaceutical Corp.	\$5,000
CIHR	\$5,000	Siemens Canada Ltd.	\$5,350

DE BOLD, ADOLFO

University of Ottawa

Natriuretic peptides and vasopeptidase inhibitors

Bristol-Myers Squibb Pharmaceutical Group	\$80,000
SOLVAY PHARMA Inc.	\$1,000
CIHR	\$5,000

FERGUSON, STEPHENJohn P. Roberts Research Institute
University of Western Ontario*Annual great lakes G-protein-coupled receptor retreat*

AstraZeneca Canada Inc.	\$2,000
Bayer Inc.	\$2,000
Merck Frosst Canada & Co.	\$9,000
CIHR	\$5,000

GOLDBERG, PETER

Royal Victoria Hospital

Acute lung injury

Pulmonex Research	\$1,000
AstraZeneca Canada Inc.	\$4,000
Eli Lilly Canada Inc.	\$10,000
Mallinckrodt Canada Inc.	\$5,000
3M Canada Inc.	\$3,000
Bristol-Myers Squibb Pharmaceutical Group	\$1,000
Pfizer Canada Inc.	\$15,000
Bayer Inc.	\$2,000
GlaxoSmithKline	\$2,000
Pharmacia Canada	\$1,500
Aventis Pharma	\$5,000
Brathwaites Olivier Medical Inc.	\$2,000
Edwards Lifesciences	\$2,000
Byk Canada Inc.	\$15,000
Alliance Pharmaceutical Corp.	\$5,000
Siemens Canada Ltd.	\$5,350
Gambro	\$500
Trudell Medical Marketing Ltd	\$250
Tyco Healthcare	\$5,000
Bird Products Corp	\$7,600
CIHR	\$5,000

GUYDA, HARVEY

McGill University

Pediatrics endocrinology – Montréal 2001 meeting

Keio University (Japan)	\$15,200
McGill University	\$10,000
Université de Montréal	\$2,000
Hospital Sainte-Justine	\$5,000
Merck Frosst Canada & Co.	\$10,000
Genentech Inc.	\$152,000
Eli Lilly & Co.	\$152,000
Novo Nordisk	\$121,600
Hoffmann-La Roche Limited	\$10,000
Pharmacia Canada	\$152,000
Diagnostic Systems Laboratories Canada	\$38,000
AstraZeneca R&D Montréal	\$34,960
Quest Diagnostics Inc. (California)	\$38,000
Quest Diagnostics Inc. (Pennsylvania)	\$6,080

Gouvernement du Québec – Tourisme Québec	\$3,805
Serono Inc.	\$106,400
Ferring AB	\$15,185
Esoterix Endocrine Sciences (California)	\$76,000
Australasia Pediatric Endocrinology	\$2,900
CIHR	\$5,000

HARRIGAN, BRIAN

University of British Columbia

Canadian association for HIV research – 9th annual conference

Bristol-Myers Squibb Pharmaceutical Group	\$10,000
Dupont Pharma	\$10,000
GlaxoSmithKline	\$25,000
Hoffmann-La Roche, Limited	\$25,000
Merck Frosst Canada & Co.	\$25,000
Sanofi-Synthelabo Canada Inc.	\$3,000
CIHR	\$5,000

LYTTON, JONATHAN

University of Calgary

Cellular and molecular physiology of sodium-calcium exchange: the IVth international conference

Carl Zeiss Canada Ltd	\$200
Alberta Heritage Foundation for Medical Research	\$10,000
Axon Instruments	\$770
Invitrogen Corp	\$250
Mandel Scientific	\$100
Merck Research Institute	\$3,080
New England Biolabs	\$350
VWR Canlab	\$100
CIHR	\$5,000

MORALES, CARLOS

McGill University

VIIth International congress of andrology

Merck Frosst Canada & Co.	\$2,000
Pfizer Canada Inc.	\$12,500
Pharmacia Canada	\$3,000
Schering Canada Inc.	\$7,198
CIHR	\$5,000

ROSSIGNOL, SERGE

Université de Montréal

23rd International Symposium – Spinal cord trauma: Neural repair and functional recovery

Merck Frosst & Canada Co.	\$5,000
AstraZeneca Canada Inc.	\$5,000
CIHR	\$5,000

WALLACE, JOHN

University of Calgary

The Banff inflammation workshop – 2001

AstraZeneca Canada Inc.	\$15,000
CIHR	\$5,000

ZANNIS-HADJOPOULOS, MARIA

McGill University

Regulation of eukaryotic DNA replication

Fisher Scientific	\$150
GlaxoSmithKline	\$1,000
Cancer Research Society Inc.	\$5,000
Laval Technopole	\$750
Johnson & Johnson Corp.	\$760
Pall Gelman Labs	\$200
New England Biolabs	\$200
Pharmacia Canada	\$2,500
CIHR	\$5,000

INDUSTRY PEER REVIEW COMMITTEE

=====

Humphries, R. Keith, Dr. (MD / PhD) Chair	Terry Fox Laboratory, British Columbia Cancer Agency
Sitar, Daniel, Dr. (PhD) Chair	Department of Pharmacology & Therapeutics, University of Manitoba
Aaron, Shawn David, Dr. (MD)	Department of Medicine, Ottawa Hospital – General Site
Acott, Philip D., Dr. (MD)	Division of Nephrology IWK-Grace Health Centre
Alfieri, Caroline, Dr. (PhD)	Sainte-Justine Hospital
Armstrong, Paul Wayne, Dr. (MD)	Division of Cardiology, University of Alberta
Befus, A. Dean, Dr. (PhD)	Pulmonary Research Group, University of Alberta
Belch, Andrew R., Dr. (MD)	Cross Cancer Institute, University of Alberta
Bell, David Arthur, Dr. (MD)	St. Joseph’s Health Center
Brash, John Law, Dr. (PhD)	Department of Chemical Engineering, McMaster University
Cameron, D. William, Prof. (MD)	Division of Infectious Diseases, Ottawa Hospital – General Site
Chan, Kwan-Leung, Dr. (MD)	University of Ottawa Heart Institute
Chow, Donna Arlene, Dr. (PhD)	Department of Immunology, University of Manitoba
Dovich, Norman J., Dr. (PhD)	Department of Chemistry, University of Washington
Duquette, Pierre, Dr. (MD)	Notre-Dame Hospital
Field, Chris, Dr. (PhD)	Department of Mathematics & Statistics, Dalhousie University
Fraser, Paul E., Dr. (PhD)	Centre for Research in Neurodegenerative Diseases, University of Toronto

Geiger, Jonathan David, Dr. (PhD)	Department of Pharmacology & Therapeutics, St. Boniface Hospital Research Centre
Hanley, David Arthur, Dr. (MD)	Health Sciences Centre, University of Calgary
Heeley, David H., Dr. (PhD)	Biochemistry Department, Memorial University
Herzberg, Gene R., Dr. (PhD)	Biochemistry Department, Memorial University
Hoffman, Paul S., Dr. (PhD)	Department of Microbiology & Immunology, Dalhousie University
Holowaty, Eric J., Dr. (MD)	Cancer Care Ontario
Hoskin, David William, Dr. (PhD)	Department of Microbiology & Immunology, Dalhousie University
Iglesias, José L., Dr. (MD)	Associate Director, Division of R&D, Eli Lilly Canada Inc.
Karlik, Stephen James, Dr. (PhD)	Diagnostic Radiology & Nuclear Medicine, University Western Ontario
Lamarre, Daniel, Dr. (PhD)	Department of Biological Sciences, R&D, Boehringer Ingelheim (Canada) Ltd.
Leclerc, Jean-Marie, Dr. (MD)	Medical Director, Schering Canada Inc.
Lesperance, Mary, Dr. (PhD)	Department of Mathematics & Statistics, University of Victoria
Lopaschuk, Gary, Dr. (PhD)	Department of Pediatrics & Pharmacology, University of Alberta
Man, Shu-Fan Paul, Dr. (MD)	Pulmonary Medicine, University of Alberta
McKelvie, Robert, Dr. (MD / PhD)	Hamilton General Hospital
Medley, John, Dr. (PhD)	Department of Mechanical Engineering, University of Waterloo
Organ, Michael G., Prof. (PhD)	Department of Chemistry, York University
Petrella, Robert John, Dr. (MD / PhD)	Centre for Activity and Aging, University of Western Ontario
Pilarski, Linda, Dr. (PhD)	Cross Cancer Institute, University of Alberta
Radomski, Marek Witold, Dr. (MD / PhD)	Department of Pharmacology, University of Alberta

Radziuk, Jerry, Dr. (MD / PhD)

Diabetes and Metabolism Research, Ottawa Hospital –
Civic Site

Roy, Sophie, Dr. (PhD)

Biochemistry and Molecular Biology,
Merck Frosst Canada and Co.

Sasyniuk, Betty, Dr. (PhD)

Department of Pharmacology, McGill University

Schryvers, Anthony B., Dr. (MD / PhD)

Department of Microbiology & Infectious Diseases,
University of Calgary

Steinhart, Allan Hillary, Dr. (MD)

Division of Gastroenterology, Mount Sinai Hospital

Teo, Koon K., Dr. (PhD)

McMaster University Medical Centre

Veldhuyzen van Zanten, Sander, Dr. (MD / PhD)

QE II, Victoria General Site, Dalhousie University

Ward, Brian James, Dr. (MD)

Montreal General Hospital

Weaver, Donald F., Dr. (MD / PhD)

Department of Medicine / Neurology, Queen’s University

Wu, Jiangping, Dr. (MD / PhD)

Laboratory of Transplantation Immunology, CHUM –
Campus Notre-Dame Research Centre

Zaky, Safwat G., Prof. (PhD)

Department of Electrical & Computer Engineering,
University of Toronto

Zowall, Hanna (M.A.)

Montreal General Hospital

Appendix D —

CIHR / Rx&D BOARD OF MANAGEMENT



Dr. Aldo Baumgartner

President and CEO
Wyeth-Ayerst Canada Inc.

Mr. Jean-Michel Halfon

President and CEO
Pfizer Canada Inc.

Dr. Alan Bernstein

President, Canadian Institutes of
Health Research

Dr. Pavel Hamet

Director of Research
CHUM – Hôtel-Dieu Campus

Dr. David Brener (*ex-officio*)

Director, Industry Programs Branch
Canadian Institutes of Health Research

Ms. Karen Mosher

Executive Director, Canadian Institutes of
Health Research

Mr. Murray Elston

President, Canada’s Research-Based
Pharmaceutical Companies (Rx&D)

Dr. Joel Weiner


Associate Dean, Research
University of Alberta

Dr. Kevin Fehr

Director, External Scientific Affairs
GlaxoSmithKline

Appendix E —

CIHR INSTITUTES



Institute of Aboriginal Peoples' Health / Dr. Jeff Reading, Toronto **Institute of Cancer Research** / Dr. Philip Branton, Montreal **Institute of Circulatory and Respiratory Health** / Dr. Bruce McManus, Vancouver **Institute of Gender and Health** / Dr. Miriam Stewart, Edmonton **Institute of Genetics** / Dr. Roderick McInnes, Toronto **Institute of Health Services and Policy Research** / Dr. Morris Barer, Vancouver **Institute of Aging** / Dr. Réjean Hébert, Sherbrooke **Institute of Human Development, Child and Youth Health** / Dr. John Challis, Toronto **Institute of Infection and Immunity** / Dr. Bhagirath Singh, London **Institute of Musculoskeletal Health and Arthritis** / Dr. Cyril B. Frank, Calgary **Institute of Neurosciences, Mental Health and Addiction** / Dr. Rémi Quirion, Montreal **Institute of Nutrition, Metabolism and Diabetes** / Dr. Diane T. Finegood, Vancouver **Institute of Population and Public Health** / Dr. John Frank, Toronto